Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2024.
Kura Oncology's investors include ARCH Venture Partners, Hercules Capital, Fidelity, Bristol-Myers Squibb, OUP (Osage University Partners).
Kura Oncology is headquartered in La Jolla, United States.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kura Oncology — Funding & Investors." VCBacked, January 24, 2024, https://www.vcbacked.co/company/kura-oncology. Accessed August 14, 2026.
VCBacked. (2024). Kura Oncology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/kura-oncology
{{cite web |title=Kura Oncology — Funding & Investors |url=https://www.vcbacked.co/company/kura-oncology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated